Invitrogen

Human ATG101 Synthetic Peptide

Product Details

PEP-1114

Applications

Tested Dilution

Publications

Control (Ctrl)

Assay-dependent

Blocking Assay (BLOCK)

Assay-dependent

Product Specifications

Species Reactivity

Human

Class

Synthetic

Type

Peptide

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

purified

Storage buffer

PBS, pH 7.2, with 0.1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C

Shipping conditions

Dry ice

Product Specific Information

This peptide corresponds to 16 amino acids near the center of human ATG101.

PEP-1114 can be used as a blocking peptide with polyclonal antibody PA5-21000.

Target Information

ATG101 is involved in autophagy, the process of bulk degradation of cellular proteins through an autophagosomic-lysosomal pathway is important for normal growth control and may be defective in tumor cells. It is involved in the preservation of cellular nutrients under starvation conditions as well as the normal turnover of cytosolic components. This process is negatively regulated by TOR (Target of rapamycin) through phosphorylation of autophagy protein ATG1. ATG101 is a recently discovered protein that stabilizes ATG13, another autophagy protein that forms a complex with the mammalian homologs of ATG1, ULK1 and ULK2, and with FIP200. This complex is a target of TOR phosphorylation under normal conditions inhibition of TOR by rapamycin or leucine deprivation leads to dephosphorylation of ATG13, ULK1 and ULK2, which then leads to autophagy. ATG101 also interacts with ULK1 and is essential for autophagy.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.